Cigna discloses USD 2.65 million lobbying spend as Cigna Group stock costs EUR 273.40
Published on 10/21/2026 at 11:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCigna adds a policy spending signal
- Cigna disclosed USD 2.65 million in third-quarter 2026 lobbying on October 21, 2026.
- The company outlined a USD 3.0 billion modernization initiative and a 10 to 14 percent adjusted EPS CAGR target through 2030.
- Cigna Group stock trades at EUR 273.40 at 11:48 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.89 percent above the Xetra close of October 20, 2026.
- The next quarterly earnings report is scheduled for November 5, 2026.
The Cigna Group (ISIN US1255231003) disclosed USD 2.65 million in third-quarter 2026 lobbying on October 21, 2026, according to Quiver Quantitative. Cigna Group stock was trading at EUR 273.40 at Lang & Schwarz at 11:48 a.m. CEST, 0.89 percent above the Xetra close of October 20, 2026.
Lobbying centers on drug costs
The filing covered prior authorization, pharmacy benefit management, drug pricing reform and healthcare transparency. It also addressed specialty drugs, Tricare pharmacy issues and the No Surprises Act, giving the disclosure a direct link to Cigna business areas.
The amount is a concrete policy signal rather than an operating result. For investors, the topics matter because pharmacy pricing and benefit administration sit close to Evernorth, one of Cigna's two main divisions.
Three milestones shape the story
On July 30, 2026, Cigna reported quarterly revenue of USD 71.56 billion and earnings per share of USD 7.78, compared with USD 7.20 a year earlier, as MarketBeat reported. On September 30, 2026, the company announced a USD 3.0 billion modernization and productivity initiative, reaffirmed adjusted 2026 revenue of about USD 280 billion and set a 10 to 14 percent adjusted EPS CAGR target through 2030, according to PR Newswire. The October 21, 2026 lobbying disclosure is the latest dated event and recorded USD 2.65 million.
What does the modernization plan mean?
The financial test is whether the planned investment can support the stated growth path. The Investor Day release also set a target of at least USD 30.45 adjusted earnings per share for 2026 and projected about USD 50 billion in cumulative operating cash flow through 2030.
When is the next report?
MindTrajour lists November 5, 2026, before the market opens, as the next quarterly reporting date. The latest structured quarterly data show second-quarter 2026 revenue of USD 71.67 billion and net income attributable to common shareholders of USD 1.66 billion.
Stock holds near its yearly high
The euro quote sits below its 52-week high of EUR 275.35 and above its 52-week low of EUR 208.40. The primary listing is on the NYSE under ticker CI, while the current German-market indication gives investors a euro reference for the session.
Cigna Group stock was trading at EUR 273.40 at Lang & Schwarz on October 21, 2026 at 11:48 a.m. CEST, 0.89 percent above the Xetra close of October 20, 2026 at EUR 271.00. The further course of trading is shown by the continuously updated real-time quote of Cigna Group stock.
Cigna Group stock facts
- Company: The Cigna Group
- ISIN: US1255231003
- Ticker: CI
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 21, 2026, 11:48 a.m. CEST): EUR 273.40
- Change versus Xetra close: plus 0.89 percent
- Xetra close (October 20, 2026): EUR 271.00
- Market capitalization: EUR 72.7 billion (as of October 21, 2026)
- 52-week range: EUR 208.40-EUR 275.35 (as of October 21, 2026)
- Sector / Industry: Healthcare / Medical - Healthcare Plans
- Next earnings date: November 5, 2026
Market context: Market report S&P 500.
